A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

The study will start with a dose-confirmation phase to establish safety of BPM31510 in combination with RT and TMZ. This phase will follow a standard 3+3 dose design with the starting dose of BPM31510 at 110 mg/kg/week (wk), with 1 potential dose de-escalation to 66 mg/kg/wk in the event a DLT is experienced at the 110 mg/kg dose. Toxicity at this dose level will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (CTCAE v5). Subjects will be monitored for DLTs associated with combination therapy for 30 days (d) (± 5 d) after the end of RT (DLT assessment period). Subjects will continue to be monitored for late radiation-related DLTs during follow up, every 8 wk (± 2 wk) during the first 12 months (mo), and then every 12 wk (± 2 wk) for a total of 5 years (y). Safety oversight will be provided by the independent Data and Safety Monitoring Committee (DSMC). The DSMC will review and confirm all DLT data, make recommendations for dose modifications, if necessary, and continue to monitor safety throughout the study. The efficacy phase of the study will begin after the recommended Phase 2 dose (RP2D) has been confirmed.

Inclusion criteria

• Subjects with newly diagnosed pathologically verified GB.
• No prior RT, chemotherapy, immunotherapy, or targeted agents administered specifically for the lesion being treated.
• Age ≥18 y.
• Life expectancy ≥3 months.
• Karnofsky performance score ≥60.
• Adequate organ and marrow function as per protocol.
• Ability for subject to understand and the willingness to sign a written ICF.
• Subjects of childbearing potential must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study.
• Be at least 15 d out and not more than 50 d from surgery.

Exclusion criteria

• History of clinically significant tumor-related cerebral hemorrhage.
• Patients with multicentric disease defined by tumors which have multiple discrete areas of contrast-enhancing tumor without connecting T2/FLAIR signal abnormality.
• Patients with diffuse leptomeningeal disease.
• Patients who are not eligible for definitive surgical resection.
• Patients on decadron daily dosing more than 2 mg.
• Any serious cardiac history as per protocol.
• Uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months.
• Known predisposition for bleeding such as von Willebrand's disease or other such condition(s).
• Uncontrolled concurrent illness.
• Prior malignancy except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 3 y prior to first dose of study drug.
• Receiving any of the following medications:

• Therapeutic doses of any anticoagulant, including low-molecular weight heparin. Concomitant use of warfarin, even at prophylactic doses, is prohibited.
• Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids.
• Antiangiogenic drugs (ie, Avastin) either in the past 2 wk or if anticipated within the next 2 wk of informed consent.
• Theophylline
• Known allergy to CoQ10.
• Known allergy or adverse reaction to Vitamin K1.
• Pregnant or lactating.
• Known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is not required for eligibility, but if performed previously and was positive, the subject is ineligible.
• Patients with a contraindication to radiation.